Articles related to DEPRESSION

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.

A Phase 2 trial of luvesilocin reported rapid reductions in postpartum depression symptoms, with most treated participants reaching remission within seven days. The investigational psychedelic has received FDA Breakthrough Therapy designation, but Phase 3 confirmation remains pending.

A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.

Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.

Breckenridge Pharmaceutical initiated a voluntary Class II recall of duloxetine delayed-release capsules 60 mg (Lot 241069C, expiration May 31, 2027) on April 21, 2026, following detection of elevated N-nitroso-duloxetine impurity levels attributed to CGMP deviations at the Barcelona manufacturing site, affecting 165,761 bottles distributed nationwide.

Suicide mortality increased among adolescents and young adults across the Americas from 2000 to 2021. Rates varied by age, sex, and region, with widening disparities observed in population-level data.